Private Capital Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Private Capital Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$200K	Buy	2,502 +181	+8%	+$17.1K	0.15%	133
2022 Q1	$244K	Sell	2,321 -16	-0.7%	-$1.56K	0.06%	194
2021 Q4	$252K	Sell	2,337 -278	-11%	-$30.3K	0.05%	209
2021 Q3	$286K	Buy	2,615 +353	+16%	+$36.6K	0.06%	181
2021 Q2	$212K	Sell	2,262 -24	-1%	-$2.21K	0.05%	227
2021 Q1	$210K	Buy	2,286 +53	+2%	+$4.47K	0.05%	215
2020 Q4	$163K	Buy	2,233 +349	+19%	+$25.9K	0.03%	355
2020 Q3	$146K	Buy	1,884 +607	+48%	+$41.8K	0.03%	350
2020 Q2	$71K	Sell	1,277 -305	-19%	-$13K	0.02%	573
2020 Q1	$47K	Sell	1,582 -165	-9%	-$5.58K	0.01%	673
2019 Q4	$63K	Sell	1,747 -70	-4%	-$2.15K	0.01%	625
2019 Q3	$50K	Buy	+1,817	New	+$47K	0.01%	784
2019 Q2	–	Sell	-1,700	Closed	-$45K	–	2521
2019 Q1	$45K	Sell	1,700 -263	-13%	-$6.23K	0.01%	833
2018 Q4	$38K	Buy	1,963 +1,150	+141%	+$22.5K	0.01%	805
2018 Q3	$15K	Buy	+813	New	+$15.5K	﹤0.01%	1289

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Private Capital Group's HZNP Position: Q2 2022 in Review

Private Capital Group increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 7.8% in Q2 2022, buying an estimated $17.1K and bringing the position to 2,502 shares worth $200K. The position accounts for 0.15% of the portfolio, ranked #133.

Private Capital Group first reported a position in HZNP in Q3 2018 and has held it in 15 quarters since. The position peaked at $286K in Q3 2021. 614 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Private Capital Group held 2,502 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $200K as of Q2 2022.
Private Capital Group bought 181 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $17.1K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.15% of Private Capital Group's portfolio in Q2 2022, its #133 holding.
Private Capital Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and has held it in 15 quarters since.
Private Capital Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $286K in Q3 2021.
614 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.